Skip to main content

Ask the News Top News Briefings Markets AI Market Briefs

Watchlist Bookmarks

Ask the News Briefings Top News News Business Sports

Top News/Health

STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns

STAT News·August 24, 2026 at 11:59 AM

statnews.com

The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged.

Chat about this story

Chat about this story… or type / for commands

Brief24 AI

More stories

STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more

STAT News·1h ago

STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more

STAT+: FDA digital health leader promises generative AI regulatory guidance is coming

STAT News·6h ago

STAT+: FDA digital health leader promises generative AI regulatory guidance is coming

STAT+: Inside Moderna and Merck’s cancer vaccine triumph

STAT News·6h ago

STAT+: Inside Moderna and Merck’s cancer vaccine triumph

STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns — Brief24

USD/EUR0.8566+0.12%
USD/GBP0.7330+0.01%
USD/JPY159.14+0.16%
USD/CHF0.8024+0.35%
USD/CAD1.383+0.39%
USD/AUD1.396-0.58%
USD/ILS2.999+0.06%
USD/CNY6.722-0.01%

Last updated 8 min ago

27°

Cloudy

High 27°

Low 18°

Mon

27°

18°

Tue

26°

16°

Wed

29°

18°

Thu

27°

22°

Fri

29°

22°

S&P 500
7,654.30-0.26%
Nasdaq
26,021.28-0.61%
Dow Jones
53,397.66+0.23%
Russell 2000
3,006.45-0.38%
VIX
15.84+4.69%
DAX
26,058.77-0.30%
Gold
$4,733.90+2.37%
Brent
$92.60-1.90%
Bitcoin
$79,671+2.46%
TA 35
4,126.55-1.09%
TA 125
4,014.95-1.09%
TA Banks-5

Last updated 8 min ago

8,842.24-0.09%